{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:42:22Z","timestamp":1777520542835,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clinre.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T20:30:40Z","timestamp":1375907440000},"page":"559-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Is HBsAg quantification ready, for prime time?"],"prefix":"10.1016","volume":"37","author":[{"given":"St\u00e9phane","family":"Chevaliez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clinre.2013.07.004_bib0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.clinre.2013.07.004_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clinre.2013.07.004_bib0015","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0025","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"9865","key":"10.1016\/j.clinre.2013.07.004_bib0035","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clinre.2013.07.004_bib0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"Management of chronic hepatitis B virus infection","volume":"57","author":"EASL clinical practice guidelines","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0055","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0060","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2010.06.026","article-title":"Hepatitis B surface antigen (HBsAg): a 40-year-old hepatitis B virus seromarker gets new life","volume":"139","author":"McMahon","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.clinre.2013.07.004_bib0065","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","author":"Chan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2013.07.004_bib0070","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0075","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2013.07.004_bib0080","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","article-title":"Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report","volume":"55","author":"Chan","year":"2011","journal-title":"J Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.clinre.2013.07.004_bib0085","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2036.2010.04474.x","article-title":"Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B","volume":"32","author":"Chan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinre.2013.07.004_bib0090","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2012.01.022","article-title":"HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years","volume":"56","author":"Fasano","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1872-034X.2012.01065.x","article-title":"Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B","volume":"43","author":"Kim","year":"2012","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.clinre.2013.07.004_bib0100","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.24221","article-title":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir","volume":"53","author":"Lee","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.clinre.2013.07.004_bib0105","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jmv.22089","article-title":"Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B","volume":"83","author":"Lee","year":"2011","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0110","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0115","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.clinre.2013.07.004_bib0120","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2893.2012.01599.x","article-title":"Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels","volume":"19","author":"Shin","year":"2012","journal-title":"J Viral Hepat"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0125","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.clinre.2013.07.004_bib0130","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"18","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","article-title":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective","volume":"52","author":"Jaroszewicz","year":"2010","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcv.2011.04.005","article-title":"A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B","volume":"51","author":"Sonneveld","year":"2011","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcv.2012.04.010","article-title":"The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays","volume":"54","author":"Verheyen","year":"2012","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0150","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcv.2010.12.008","article-title":"Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum","volume":"50","author":"Wursthorn","year":"2011","journal-title":"J Clin Virol"},{"issue":"8","key":"10.1016\/j.clinre.2013.07.004_bib0155","doi-asserted-by":"crossref","first-page":"e43143","DOI":"10.1371\/journal.pone.0043143","article-title":"Hepatitis B surface antigen concentrations in patients with HIV\/HBV co-infection","volume":"7","author":"Jaroszewicz","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/CVI.05454-11","article-title":"Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus","volume":"19","author":"Maylin","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.clinre.2013.07.004_bib0165","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1537-2995.2008.01701.x","article-title":"Hepatitis B virus infection and transfusion medicine: science and the occult","volume":"48","author":"Hollinger","year":"2008","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0170","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","article-title":"Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia","volume":"52","author":"Nguyen","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2013.07.004_bib0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol Mol Biol Rev"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jhep.2009.12.020","article-title":"A new role for an old marker, HBsAg","volume":"52","author":"Brunetto","year":"2010","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0185","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.21811","article-title":"Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B","volume":"46","author":"Feld","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0190","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0168-8278(02)00004-1","article-title":"Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers","volume":"36","author":"Martinot-Peignoux","year":"2002","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2013.07.004_bib0195","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/01.meg.0000170926.83850.dd","article-title":"Serum hepatitis B virus DNA levels differentiating inactive carriers from patients with chronic hepatitis B","volume":"17","author":"Seo","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0200","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0205","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jir283","article-title":"Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"204","author":"Chan","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0210","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.23803","article-title":"A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B","volume":"52","author":"Chan","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0215","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/hep.24473","article-title":"Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0220","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2013.07.004_bib0225","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1440-1746.2010.06282.x","article-title":"Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients","volume":"25","author":"Ma","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2013.07.004_bib0230","first-page":"151","article-title":"On-treatment decline in serum HBsAg levals predicts sustained immune control 1 year post-treatment and subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peinterferon alpha-2a","volume":"4","author":"Marcellin","year":"2010","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.clinre.2013.07.004_bib0235","first-page":"152","article-title":"On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 months pots-treatment in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alpha-2a","volume":"4","author":"Piratvisuth","year":"2010","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.clinre.2013.07.004_bib0240","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.clinre.2013.07.004_bib0245","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2013.07.004_bib0250","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1111\/j.1365-2893.2011.01473.x","article-title":"Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients","volume":"18","author":"Gramenzi","year":"2011","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.clinre.2013.07.004_bib0255","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2013.07.004_bib0260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350701200107","article-title":"Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels","volume":"12","author":"Manesis","year":"2007","journal-title":"Antivir Ther"},{"issue":"8","key":"10.1016\/j.clinre.2013.07.004_bib0265","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e328352224d","article-title":"Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients","volume":"26","author":"Maylin","year":"2012","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.clinre.2013.07.004_bib0270","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3851\/IMP1723","article-title":"Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients","volume":"16","author":"Thibault","year":"2011","journal-title":"Antivir Ther"},{"issue":"9","key":"10.1016\/j.clinre.2013.07.004_bib0275","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1128\/JCM.00971-12","article-title":"Long-term hepatitis B virus surface antigen decay in HIV-1\/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen","volume":"50","author":"Tuaillon","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.clinre.2013.07.004_bib0280","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis439","article-title":"Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV","volume":"206","author":"Zoutendijk","year":"2012","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0285","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/135965350701200307","article-title":"Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring","volume":"12","author":"Manesis","year":"2007","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.clinre.2013.07.004_bib0290","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinre.2013.07.004_bib0295","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2009.02140.x","article-title":"Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis","volume":"30","author":"Zachou","year":"2010","journal-title":"Liver Int"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113001472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113001472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:18:55Z","timestamp":1761895135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740113001472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S2210740113001472"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2013.07.004","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is HBsAg quantification ready, for prime time?","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2013.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}